Latest
Recommended
Published: Sat, March 04, 2017
Economy | By Melissa Porter

Revenue Estimates Analysis of: Sangamo Biosciences Inc. (NASDAQ:SGMO)


Jefferies Group also issued estimates for Sangamo BioSciences' Q3 2017 earnings at ($0.33) EPS, Q4 2017 earnings at ($0.32) EPS, FY2017 earnings at ($1.19) EPS, FY2018 earnings at ($1.21) EPS, FY2019 earnings at ($1.14) EPS and FY2020 earnings at ($1.28) EPS.

Sangamo BioSciences (NASDAQ:SGMO) last issued its quarterly earnings results on Tuesday, February 28th. (NASDAQ:SGMO) reported its Actual EPS of $-0.27/share. The company had revenue of $8.90 million for the quarter, compared to analyst estimates of $3.91 million. Sangamo BioSciences had a negative return on equity of 45.02% and a negative net margin of 388.23%. Sangamo BioSciences's revenue was down 2.2% on a year-over-year basis. (NASDAQ:SGMO)'s shares have the potential to reach a high EPS of -0.24 per share, and a low EPS of -0.27 per share in the current quarter.

This report was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US and worldwide copyright and trademark law.

SGMO has been the topic of several other research reports. Finally, Piper Jaffray Companies reissued a "neutral" rating and issued a $5.00 target price on shares of Sangamo BioSciences in a research report on Tuesday. Stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 3 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Finally, Cowen and Company reaffirmed a "buy" rating on shares of Sangamo BioSciences in a research note on Tuesday. Janney Capital Initiates Coverage on the company's stock to Buy on 12/17/15 with no specific Price Target.

Sangamo Biosciences Inc. (NASDAQ:SGMO) now has a consensus Price Target of $7.

Sangamo Biosciences Inc. (NASDAQ:SGMO) topped its 52-week high price target of 7.6 on Jun 7, 2016. 4 Analysts reported that the Price Target for Sangamo Biosciences Inc. might touch $14 high while the Average Price Target and Low price Target is $7 and $4 respectively.

The stock's price switched up 18.57% 20-Days Simple Moving Average, added 25.21% from 50-Days Simple Moving Average and fell -0.75% from 200 Days Simple Moving Average. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Wasatch Advisors Inc. now owns 6,981,681 shares of the biopharmaceutical company's stock valued at $32,325,000 after buying an additional 26,920 shares during the period. Deerfield Management Co. purchased a new position in Sangamo BioSciences during the fourth quarter worth about $2,556,000. Opaleye Management Inc. bought a new position in Sangamo BioSciences during the fourth quarter worth approximately $1,220,000. NY raised its position in Sangamo BioSciences by 1.6% in the fourth quarter.

In the last trading session, The Company traded 2.55 Million shares. Quantitative Systematic Strategies LLC bought a new position in shares of Sangamo BioSciences during the second quarter worth approximately $163,000. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. "We are using our ZFN mediated genome editing approach in three Phase 1/2 clinical trials, for lysosomal storage disorders MPS I and MPS II and for hemophilia B. By year end 2017 or early in 2018 we expect data from these three studies and from our fourth lead clinical program, a promising gene therapy for hemophilia A".

Like this: